RU2008116931A - Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей - Google Patents

Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей Download PDF

Info

Publication number
RU2008116931A
RU2008116931A RU2008116931/14A RU2008116931A RU2008116931A RU 2008116931 A RU2008116931 A RU 2008116931A RU 2008116931/14 A RU2008116931/14 A RU 2008116931/14A RU 2008116931 A RU2008116931 A RU 2008116931A RU 2008116931 A RU2008116931 A RU 2008116931A
Authority
RU
Russia
Prior art keywords
desmethylclozapine
psychosis
subject
effective amount
therapeutically effective
Prior art date
Application number
RU2008116931/14A
Other languages
English (en)
Inventor
Дэвид М. УЭЙНЕР (US)
Дэвид М. УЭЙНЕР
Марк Р. БРЭНН (US)
Марк Р. БРЭНН
Original Assignee
Акадиа Фармасьютикалз Инк. (Us)
Акадиа Фармасьютикалз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акадиа Фармасьютикалз Инк. (Us), Акадиа Фармасьютикалз Инк. filed Critical Акадиа Фармасьютикалз Инк. (Us)
Publication of RU2008116931A publication Critical patent/RU2008116931A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1. Способ улучшения состояния при психозе любого происхождения, с одновременным увеличением уровня активности мускаринового рецептора, включающий введение субъекту, нуждающемуся в этом, терапевтически эффективное количество N-десметилклозапина. ! 2. Способ по п.1, в котором субъект является человеком. ! 3. Способ по п.1, в котором терапевтически эффективное количество N-десметилклозапина вводят в виде единичной дозы. ! 4. Способ по п.1, в котором терапевтически эффективное количество N-десметилклозапина вводят в виде многократных доз. ! 5. Способ по п.1, в котором психоз ассоциирован с шизофренией. ! 6. Способ по п.1, в котором психоз ассоциирован с болезнью Альцгеймера. ! 7. Способ по п.1, в котором введение N-десметилклозапина дополнительно улучшает состояние при когнитивном нарушении любого происхождения. ! 8. Способ по п.1, включающий введение субъекту фармацевтической композиции, включающей N-десметилклозапин и фармацевтически приемлемый разбавитель или эксципиент. ! 9. Способ по п.8, в котором фармацевтическая композиция включает от 0,01 до 1000 мг N-десметилклозапина. ! 10. Способ по п.1, где мускариновый рецептор представляет собой рецептор М1.

Claims (10)

1. Способ улучшения состояния при психозе любого происхождения, с одновременным увеличением уровня активности мускаринового рецептора, включающий введение субъекту, нуждающемуся в этом, терапевтически эффективное количество N-десметилклозапина.
2. Способ по п.1, в котором субъект является человеком.
3. Способ по п.1, в котором терапевтически эффективное количество N-десметилклозапина вводят в виде единичной дозы.
4. Способ по п.1, в котором терапевтически эффективное количество N-десметилклозапина вводят в виде многократных доз.
5. Способ по п.1, в котором психоз ассоциирован с шизофренией.
6. Способ по п.1, в котором психоз ассоциирован с болезнью Альцгеймера.
7. Способ по п.1, в котором введение N-десметилклозапина дополнительно улучшает состояние при когнитивном нарушении любого происхождения.
8. Способ по п.1, включающий введение субъекту фармацевтической композиции, включающей N-десметилклозапин и фармацевтически приемлемый разбавитель или эксципиент.
9. Способ по п.8, в котором фармацевтическая композиция включает от 0,01 до 1000 мг N-десметилклозапина.
10. Способ по п.1, где мускариновый рецептор представляет собой рецептор М1.
RU2008116931/14A 2003-01-23 2008-04-28 Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей RU2008116931A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44269003P 2003-01-23 2003-01-23
US60/442,690 2003-01-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2005126614/15A Division RU2336879C2 (ru) 2003-01-23 2004-01-21 Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей

Publications (1)

Publication Number Publication Date
RU2008116931A true RU2008116931A (ru) 2009-11-10

Family

ID=32772052

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2005126614/15A RU2336879C2 (ru) 2003-01-23 2004-01-21 Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей
RU2008116931/14A RU2008116931A (ru) 2003-01-23 2008-04-28 Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2005126614/15A RU2336879C2 (ru) 2003-01-23 2004-01-21 Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей

Country Status (14)

Country Link
US (2) US20040224942A1 (ru)
EP (2) EP1589974A2 (ru)
JP (1) JP2006515628A (ru)
KR (1) KR20050092123A (ru)
CN (1) CN1741803A (ru)
AU (1) AU2004206931A1 (ru)
BR (1) BRPI0406592A (ru)
CA (1) CA2512043A1 (ru)
MX (1) MXPA05007784A (ru)
NZ (1) NZ541014A (ru)
RU (2) RU2336879C2 (ru)
SG (1) SG159390A1 (ru)
WO (1) WO2004064753A2 (ru)
ZA (1) ZA200505878B (ru)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080059687A (ko) 2000-03-06 2008-06-30 아카디아 파마슈티칼스 인코포레이티드 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물
WO2003057698A2 (en) 2001-12-28 2003-07-17 Acadia Pharmaceuticals, Inc. Spiroazacyclic compounds as monoamine receptor modulators
NZ537522A (en) 2002-06-24 2006-07-28 Acadia Pharm Inc N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
MXPA05007568A (es) 2003-01-16 2005-09-21 Acadia Pharm Inc Agonistas inversos del receptor selectivo de serotonina 2a/2c como terapeuticos para enfermedades neurodegenerativas.
MXPA05007784A (es) * 2003-01-23 2005-09-30 Acadia Pharm Inc Empleo de la n-desmetilclozapina para tratar las enfermedades neuropsiquiatricas humanas.
WO2006017614A1 (en) * 2004-08-05 2006-02-16 Acadia Pharmaceuticals Inc. Use of n-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20060233843A1 (en) * 2003-02-19 2006-10-19 Conn P J Treatment of psychosis with a muscarinic m1 receptor ectopic activator
US20090093460A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Compositions
US20060252743A1 (en) * 2005-01-07 2006-11-09 Astrazeneca Ab Method of treating sleep disorders
US20060229292A1 (en) * 2005-01-07 2006-10-12 Astrazeneca Ab Method of treating childhood disorders
US20060217366A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating schizophrenia and other disorders
US20060217365A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating mood disorders
AU2004253334A1 (en) * 2003-07-02 2005-01-13 Astrazeneca Ab Metabolite of quetiapine
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US20060217367A1 (en) * 2004-07-01 2006-09-28 Astrazeneca Ab Method of treating anxiety disorders
US20070117789A1 (en) * 2005-11-18 2007-05-24 Astrazeneca Ab Method of treatment
CN101962369A (zh) * 2003-12-22 2011-02-02 阿卡蒂亚药品公司 氨基取代的二芳基[a,d]环庚烯类似物作为毒蕈碱激动剂的用途及神经精神疾病的治疗方法
US20090239840A1 (en) * 2003-12-22 2009-09-24 Acadia Pharmaceuticals, Inc. AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
CN1950346A (zh) * 2004-04-01 2007-04-18 阿卡蒂亚药品公司 N－去甲基氯氮平的晶形
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
PL2289879T3 (pl) 2004-09-27 2015-05-29 Acadia Pharm Inc Synteza formy krystalicznej soli winianowej n-(4-fluorobenzylo)-n-(1-metylopiperydyn-4-ylo)-n'-(4-(2-metylopropyloksy)fenylometylo)karbamidu
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
CA2599922A1 (en) * 2005-04-04 2006-10-12 Acadia Pharmaceuticals Inc. Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents
US7678363B2 (en) * 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
US20070105836A1 (en) * 2005-10-31 2007-05-10 Lars Pettersson Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
WO2007148341A2 (en) 2006-06-22 2007-12-27 Ramot At Tel Aviv University Ltd. Novel serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity
US9278947B2 (en) 2006-06-22 2016-03-08 Ramot At Tel-Aviv University Ltd. Serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity
WO2008116024A2 (en) 2007-03-19 2008-09-25 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
PE20110029A1 (es) * 2008-06-20 2011-02-11 Astrazeneca Ab Derivados de dibenzotiazepina
US9018202B2 (en) * 2010-12-03 2015-04-28 Allergan, Inc. Methods for treating diseases of the retina
RU2506073C1 (ru) * 2012-09-06 2014-02-10 Алексей Николаевич Паршин Способ лечения расстройства адаптации у пациентов с суицидальным риском
WO2016109679A1 (en) * 2014-12-31 2016-07-07 Markovitz M D Ph D Paul Method of treating schizophrenia
PT3325444T (pt) 2015-07-20 2021-09-22 Acadia Pharm Inc Métodos para preparar n-(4-fluorobenzil)-n-(1-metilpiperidina-4-il)-n'-(4-(2-metilpropiloxi)fenilmetil)carbamida e o seu sal de tartarato e forma polimórfica c
US20190008850A1 (en) * 2015-12-30 2019-01-10 Paul J. Markovitz Method of treating schizophrenia
RU2667954C2 (ru) * 2016-03-04 2018-09-25 Общество С Ограниченной Ответственностью "Валентек" Фармацевтическая композиция для лечения функциональных психических расстройств
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
WO2018118626A1 (en) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
EP3615028A1 (en) 2017-04-28 2020-03-04 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN107970243B (zh) * 2017-10-30 2020-07-28 江苏理工学院 一种去甲氯氮平的新用途
CN109761826B (zh) * 2019-01-17 2022-02-25 烟台大学 一种o-去甲基文拉法辛苯醚化合物及其制备方法和用途
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) * 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
US3389139A (en) * 1963-06-14 1968-06-18 Wander Ag Dr A 6-homopiperazino and piperazinomorphanthridines
US3884920A (en) * 1967-07-14 1975-05-20 Sandoz Ag 11-Basically substituted dibenz {8 b,f{9 {0 {8 1,4{9 {0 oxazepines
US3908010A (en) * 1967-03-22 1975-09-23 Wander Ag Dr A Basically substituted heterocycles as anti-emetics
US3412193A (en) * 1965-12-13 1968-11-19 American Cyanamid Co 11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepines or thiazepines for controlling fertility
AT278805B (de) * 1966-01-17 1970-02-10 American Cyanamid Co Verfahren zur herstellung von oxazepinen und thiazepinen
GB1184251A (en) * 1966-04-15 1970-03-11 American Cyanamid Co Oxazepines and Thiazepines
GB1192812A (en) * 1966-05-20 1970-05-20 American Cyanamid Co 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts
US3852446A (en) * 1967-03-13 1974-12-03 Sandoz Ag Organic compounds in treatment of psychotic disturbances
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3758479A (en) * 1967-03-22 1973-09-11 Sandoz Ag Nitro and sulphamoyl substituted dibenzodiazepines
US3751415A (en) * 1967-03-22 1973-08-07 Sandoz Ag 2-nitro-11-(1-piperazinyl)-dibenz(b,f)(1,4)oxazepines
CA918659A (en) * 1969-07-31 1973-01-09 Yoshitomi Pharmaceutical Industries 11-(4-substituted-1-piperazinyl)-dibenzo (b,f) (1,4) thiazepines
US3660406A (en) * 1970-10-26 1972-05-02 American Cyanamid Co 2-chloro-7-hydroxy-11-(1-piperazinyl)dibenz(b f)(1 4)oxazepines
CH555856A (de) * 1971-05-04 1974-11-15 Hoffmann La Roche Verfahren zur herstellung von tricyclischen verbindungen.
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
US3884446A (en) * 1973-12-10 1975-05-20 Dahl Co G W Low profile control valve actuator
US3983234A (en) * 1974-07-04 1976-09-28 Sandoz Ltd. Treatment of dyskinesias
US4045445A (en) * 1975-12-14 1977-08-30 American Cyanamid Company 11-(4-Piperidyl)dibenzo-diazepines
CH624682A5 (ru) * 1976-11-10 1981-08-14 Sandoz Ag
US4406900A (en) * 1976-11-10 1983-09-27 Sandoz Ltd. Neuroleptic use of morphanthridines
US4096261A (en) * 1977-02-23 1978-06-20 Abbott Laboratories Dibenzodiazepines
US4097597A (en) * 1977-02-23 1978-06-27 Abbott Laboratories Dibenzo b,e! 1,4!diazepines
US4191760A (en) * 1977-02-23 1980-03-04 Abbott Laboratories Dibenzodiazepines
CS196893B1 (en) * 1977-12-22 1980-04-30 Miroslav Protiva 3-fluor-10-piperazino-8-substituted 10,11-dihydro-dibenzothiepines
US4263207A (en) * 1978-08-01 1981-04-21 Merck & Co., Inc. 10,11-Dihydrodibenzo[b,f][1,4]thiazepine carboxylic acids esters and amides thereof
US4268207A (en) * 1979-07-06 1981-05-19 Eaton Corporation Load support and shuttle
US4404137A (en) * 1979-10-16 1983-09-13 Lilly Industries Limited Pyrazolo [3,4-b][1,5]benzodiazepine compounds
CH641876A5 (de) * 1980-02-14 1984-03-15 Sulzer Ag Kolbenkompressor, insbesondere zum verdichten von sauerstoff.
US4764616A (en) * 1983-05-18 1988-08-16 Hoechst-Roussel Pharmaceuticals Inc. Benzopyrrolobenzodiazepines and quinobenzodiazepines
US4663453A (en) * 1983-05-18 1987-05-05 Hoechst-Roussel Pharmaceuticals Inc. Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor activity
JPH04211071A (ja) * 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
US5817655A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Methods of treatment using a thieno-benzodiazepine
US5300422A (en) * 1991-12-04 1994-04-05 Case Western Reserve University Screening method for controlling agranulocytosis
US5393752A (en) * 1992-05-26 1995-02-28 Therabel Research S.A./N.V. Methylpiperazinoazepine compounds, preparation and use thereof
US5962664A (en) * 1993-05-13 1999-10-05 Friedhoff; Arnold J. Psychosis protecting nucleic acid, peptides, compositions and method of use
US5354747A (en) * 1993-06-16 1994-10-11 G. D. Searle & Co. 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
IL110298A (en) * 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
US5538965A (en) * 1993-12-23 1996-07-23 Allelix Biopharmaceuticals Inc. Dopamine receptor ligands
US6566065B1 (en) * 1994-05-26 2003-05-20 Mcgill University Method of diagnosing schizophrenia by detecting a mutation in the (MTHFR) gene
US5602124A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
US5602121A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. Alkyl-substituted compounds having dopamine receptor affinity
US5602120A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. Benzyl-substituted compounds having dopamine receptor affinity
US5700445A (en) * 1994-12-12 1997-12-23 Allelix Biopharmaceuticals, Inc. N-methyl piperazine compounds having dopamine receptor affinity
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
AU5919001A (en) * 2000-04-28 2001-11-12 Acadia Pharm Inc Muscarinic agonists
AU2002249885A1 (en) * 2000-11-17 2002-08-12 Adolor Corporation Delta agonist analgesics
WO2004026030A2 (en) * 2002-09-18 2004-04-01 Fmc Corporation Insecticidal tricyclic derivatives
BR0317528A (pt) * 2002-12-20 2005-11-22 Basf Ag Uso dos compostos, métodos para o controle de insetos, aracnìdeos ou nematodos, e para a proteção de plantas em crescimento contra o ataque ou a infestação por insetos, aracnìdeos ou nematodos, compostos, e, composições
MXPA05007568A (es) * 2003-01-16 2005-09-21 Acadia Pharm Inc Agonistas inversos del receptor selectivo de serotonina 2a/2c como terapeuticos para enfermedades neurodegenerativas.
US20070275957A1 (en) * 2003-01-23 2007-11-29 Weiner David M Use of n-desmethylclozapine to treat human neuropsychiatric disease
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
MXPA05007784A (es) * 2003-01-23 2005-09-30 Acadia Pharm Inc Empleo de la n-desmetilclozapina para tratar las enfermedades neuropsiquiatricas humanas.
US20060233843A1 (en) * 2003-02-19 2006-10-19 Conn P J Treatment of psychosis with a muscarinic m1 receptor ectopic activator
CN101962369A (zh) * 2003-12-22 2011-02-02 阿卡蒂亚药品公司 氨基取代的二芳基[a,d]环庚烯类似物作为毒蕈碱激动剂的用途及神经精神疾病的治疗方法
CN1950346A (zh) * 2004-04-01 2007-04-18 阿卡蒂亚药品公司 N－去甲基氯氮平的晶形
US20060063755A1 (en) * 2004-09-21 2006-03-23 Edgar Dale M Loxapine analogs and methods of use thereof
US20060063754A1 (en) * 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder
CA2599922A1 (en) * 2005-04-04 2006-10-12 Acadia Pharmaceuticals Inc. Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents
US20070105836A1 (en) * 2005-10-31 2007-05-10 Lars Pettersson Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders

Also Published As

Publication number Publication date
CA2512043A1 (en) 2004-08-05
WO2004064753A2 (en) 2004-08-05
US20090018119A1 (en) 2009-01-15
ZA200505878B (en) 2006-04-26
CN1741803A (zh) 2006-03-01
EP1994932A1 (en) 2008-11-26
BRPI0406592A (pt) 2005-12-20
NZ541014A (en) 2008-05-30
RU2336879C2 (ru) 2008-10-27
KR20050092123A (ko) 2005-09-20
US20040224942A1 (en) 2004-11-11
MXPA05007784A (es) 2005-09-30
AU2004206931A1 (en) 2004-08-05
RU2005126614A (ru) 2006-01-27
JP2006515628A (ja) 2006-06-01
WO2004064753A3 (en) 2004-11-25
EP1589974A2 (en) 2005-11-02
SG159390A1 (en) 2010-03-30

Similar Documents

Publication Publication Date Title
RU2008116931A (ru) Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей
ES2393815T3 (es) Agonistas opioides kappa para el tratamiento de síndrome del intestino irritable con diarrea predominante y alternante
EA200800881A1 (ru) Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами
WO1999047158A3 (en) Therapeutic chemokine receptor antagonists
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
IL189546A0 (en) Therapy for the treatment of disease
JP2006501240A5 (ru)
NZ593467A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
GB2285219A (en) Use of norastemizole for the treatment of allergic disorders
MX2024006271A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JPH08291077A (ja) 骨萎縮改善剤
Wang et al. Differentiating effects of anisodamine on cognitive amelioration and peripheral muscarinic side effects induced by pilocarpine in mice
RU2005131578A (ru) Аплидин для лечения множественной миеломы
RU2013149635A (ru) Соединения солифенацина и слюнные стимулянты для лечения гиперактивности мочевого пузыря
RU2005135649A (ru) Комбинации пароксетина и 4-(s)-(4-ацетилпиперазин-1-ил)-2-(r)-(4-фтор-2-метилфенил)пиперидин-1-карбоновой кислоты [1-(r)-(3, 5-бис-трифторметилфенил)этил]метиламида для лечения депрессии и/или тревоги
MX2024006270A (es) Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
RU2002129298A (ru) Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера
RU2003130641A (ru) Каппа-опиатные агонисты для лечения заболеваний мочевого пузыря
JP2008106028A (ja) 慢性疼痛の治療におけるフリバンセリンの使用
EP1535616A4 (en) MEDICAMENT FOR SYNDROME OF INTEGRATION DYSFUNCTION
US20090124606A1 (en) Composition for Treatment of Psychosis
CA2480275A1 (en) Statin therapy for enhancing cognitive maintenance

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20110429